A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma

Annals of Hematology

Volumn 85, Issue 5, 2006, Pages 301-307

  Waselenko, Jamie K ^a,b   Reese, Amy ^b   Park, Kathy ^b   Lucas, Margaret ^c   Goodrich, Amy ^d   Willis, Carl R ^b,e   Diehl, Louis F ^d,f   Grever, Michael R ^c   Byrd, John C ^c   Flinn, Ian W ^d  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e Nashville Surgical Associates   (United States)

^f DUKE UNIVERSITY   (United States)

Author keywords

Chlorambucil; Chronic lymphocytic leukemia; Follicular lymphoma; Non Hodgkin's lymphoma; Pentostatin; Theophylline

Indexed keywords

ACICLOVIR; CHLORAMBUCIL; COTRIMOXAZOLE; DAPSONE; FLUDARABINE; GRANISETRON; PENTOSTATIN; PLACEBO; SODIUM CHLORIDE; THEOPHYLLINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; B CELL LEUKEMIA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG ERUPTION; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HERPES ZOSTER; HUMAN; HYDRATION; INFECTION; KIDNEY FAILURE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; LUNG TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTOSIS; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, B-CELL, CHRONIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PENTOSTATIN; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE; THEOPHYLLINE;

EID: 33646681429     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-0025-9     Document Type: Article

References (29)

1. Hermine O, Haioun C, Lepage E et al (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87(1):265-272
2. Reed JC (1997) Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 34(4 Suppl 5):9-19
3. Dohner H, Fischer K, Bentz M et al (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85(6):1580-1589
4. Ichikawa A, Kinoshita T, Watanabe T et al (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337(8):529-534
5. Giles FJ, Bekele BN, O'Brien S et al (2003) A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol 121(4):578-585
6. Faderl S, Keating MJ, Do KA et al (2002) Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 16(6):1045-1052
7. Grever MR, Siaw MF, Jacob WF et al (1981) The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 57(3):406-417
8. Grever MR, Leiby JM, Kraut EH et al (1985) Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 3(9):1196-1201
9. Cummings FJ, Kim K, Neiman RS et al (1991) Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 9(4):565-571
10. Dillman RO, Mick R, McIntyre OR (1989) Pentostatin in chronic lymphocytic leukemia: A phase II trial of cancer and leukemia group B. J Clin Oncol 7(4):433-438
11. Johnson SA, Catovsky D, Child JA, Newland AC, Milligan DW, Janmohamed R (1998) Phase I/II evaluation of pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. Invest New Drugs 16(2):155-160
12. Johnston JB, Verburg L, Shore T, Williams M, Israels LG, Begleiter A (1994) Combination therapy with nucleoside analogs and alkylating agents. Leukemia 8(Suppl 1):S140-S143
13. O'Brien SM, Kantarjian HM, Cortes J et al (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19(5):1414-1420
14. Oken MM, Lee S, Kay NE, Knospe W, Cassileth PA (2004) Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk Lymphoma 45(1):79-84
15. Mentz F, Mossalayi MD, Ouaaz F et al (1996) Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells. Blood 88(6):2172-2182
16. Wiernik PH, Paietta E, Goloubeva O et al (2004) Phase II study of theophylline in chronic lymphocytic leukemia: A study of the Eastern Cooperative Oncology Group (E4998). Leukemia 18(10):1605-1610
17. Mabed M, Aref S, Fouda M, El-Sharawy S (2004) Chlorambucil plus theophylline vs chlorambucil alone as a front line therapy for B-cell chronic lymphatic leukemia. Leuk Lymphoma 45(10):2029-2035
18. Cheson BD, Bennett JM, Grever M et al (1996) National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87(12):4990-4997
19. Weiss MA, Maslak PG, Jurcic JG et al (2003) Pentostatin and cyclophosphamide: An effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 21(7):1278-1284
20. Mentz F, Merle-Beral H, Ouaaz F, Binet JL (1995) Theophylline, a new inducer of apoptosis in B-CLL: Role of cyclic nucleotides. Br J Haematol 90(4):957-959
21. Mentz F, Merle-Beral H, Dalloul AH (1999) Theophylline-induced B-CLL apoptosis is partly dependent on cyclic AMP production but independent of CD38 expression and endogenous IL-10 production. Leukemia 13(1):78-84
22. Keating MJ, O'Brien S, Kontoyiannis D et al (2002) Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 43(9):1755-1762
23. Perkins JG, Flynn JM, Howard RS, Byrd JC (2002) Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: Implications for clinical trials in this patient population. Cancer 94(7):2033-2039
24. Byrd JC, Peterson B, Piro L et al (2003) A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: Results from CALGB Study 9211. Leukemia 17(2):323-327
25. Rai KR, Peterson BL, Appelbaum FR et al (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343(24):1750-1757
26. Keating MJ, O'Brien S, Robertson L, Huh Y, Kantarjian H, Plunkett W (1993) Chronic lymphocytic leukemia-correlation of response and survival. Leuk Lymphoma 11(Suppl 2):167-175
27. Oudat R, Keating MJ, Lerner S, O'Brien S, Albitar M (2002) Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission. Leukemia 16(4):632-635
28. Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D (2004) A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 104(2):328-335
29. Harris NL, Jaffe ES, Diebold J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17(12):3835-3849